drugset / Trial / NCT04673266
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Phase 2
Completed
11 enrolled
Memorial Sloan Kettering Cancer Center
Amgen · collabTel-Aviv Sourasky Medical Center · collabUniversity of Miami Sylvester Comprehensive Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfusions. In addition, we will determine how safe it is to give romiplostim to people with lymphoma who have low platelet count from chemotherapy.
Timeline
- Start
- 2020-12-14
- Primary completion
- 2026-04-07
- Completion
- 2026-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romiplostim | Peptide | 3 ug/kg | Subcutaneous |